Enterprise Value to EBITDA Ratio: Personalis, Inc. (PSNL)
Personalis, Inc. (PSNL) operates a business that is insulated from market cycles, as demand for cancer diagnostics remains stable, although it depends on government budgets. Efficient express delivery of biomaterials supports high operational profitability. To conduct tests, Personalis, Inc. (PSNL) engages external contractors, thereby diversifying its partner pool. The EV/EBITDA valuation multiple history reflects debt load dynamics, where the metric value stands at 0.00.
Financial and market metric breakdowns for personalis.com (PSNL)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Personalis, Inc.|PSNL - Long-Term Liabilities to Equity|Short-Term Debt to Capital Personalis|PSNL - Company Cumulative Debt|Debt to Book Capitalization Ratio Personalis Genomics|PSNL - Company Long-Term Loans and Borrowings|Company Short-Term Debt Personalis|Quick Liquidity personalis.com
- business earnings and investment ratios data:
PSNL - Company Net Income|Expected Profit Personalis, Inc.|PSNL - Price to Earnings Multiple|Forward P/E Multiple Personalis, Inc.|PSNL - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Personalis Genomics|PSNL - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Personalis|PSNL - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months personalis.com|PSNL - Expected net earnings per share growth this year|Expected earnings per share growth for next year Personalis, Inc.
Initial company analysis:PSNL (Personalis Corp)
The EV/EBITDA multiple determines the total enterprise value relative to its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA multiple, an investor assesses the payback period of assets inclusive of net debt, which is critical for Personalis, Inc. (PSNL) due to high R&D expenditures and a reliance on partnerships, where financial stability is currently hovering at the edge of acceptable levels.
Key competitors
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Erasca Oncology ERAS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Delcath Systems, Inc. (DCTH)|YMAB: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AURA (Aura Biosciences)|Candel Therapeutics Inc. (CADL) - Company Value to EBITDA|ARAY - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation SLS (SELLAS Life Sciences)|Actuate Therapeutics, Inc. (ACTU) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CTOR - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TuHURA Biosciences Inc.|Company Value to EBITDA Protara Therapeutics Inc TARA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Fate Therapeutics Corp (FATE)|aadibio.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TCRX (TScan Therapeutics, Inc.)|EV/EBITDA Multiple Champions Oncology Inc CSBR|XBIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CVM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OSTX: EV/EBITDA Multiple|RADX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Adlai Nortye Limited (ANL) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio VERU (Veru)|TPST (Tempest Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple XLO (Xilio Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Renovaro Biosciences (RENB)|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KAPA (Kairos Pharma Ltd) - Enterprise Value to Operating Income Before Depreciation|OKUR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CytoMed Therapeutics Limited|Enterprise Value to EBITDA Ratio CRIS|Apollomics Corp (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune, Inc. (THAR)|ADVB: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex GNPX|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIO (Xenetic Biosciences) - Enterprise Value to Operating Income Before Depreciation|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PPBT (purple-biotech.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeiGene Ltd. (BGNE)|EV/EBITDA Multiple CKPT|EV/EBITDA Multiple Elevation Oncology Inc. (ELEV)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR: EV/EBITDA Multiple|Company Value to EBITDA NAYA Biosciences Corp (NAYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
